Volume: July 2024, Issue 1

Jul 8, 2024 | Hot Topics

AARS News

  • AARS July Membership Discount Available to HCPs
  • Amid Paucity of Innovation, New Acne Treatment Guidelines Overlook Critical Issues: Editorial
  • AARS Spotlights #AcneFacts During National Acne Awareness Month
  • AARS Goes One-on-One with Dermatologist Sandra Lee, MD aka Dr. Pimple Popper

New Medical Research

  • Dezocine as preemptive analgesia alleviates ultrapulse CO2 fractional laser treatment induced pain in patients with acne scars.
  • Potential of cannabidiol as acne and acne scar treatment: Novel insights into molecular pathways of pathophysiological factors.
  • Development and implementation of an online intervention and embedded decision aid to support self-management of acne vulgaris: Qualitative interviews with healthcare professionals.
  • Effects of spironolactone on skin biophysical properties in women with acne treated with oral spironolactone.
  • Fractional radiofrequency and oral isotretinoin-A prospective randomized controlled split-face trial comparing concurrent versus delayed fractional radiofrequency treatment for acne scars.
  • A seven-week, open-label trial evaluating the safety and efficacy of a photopneumatic device for mitigating mild-to-moderate acne in healthy adolescents and young adults.
  • Pharmacological management and potentially inappropriate prescriptions for patients with acne.
  • International expert consensus recommendations for the use of dermocosmetics in acne
  • Repurposing lipid-lowering drugs as potential treatment for acne vulgaris: A Mendelian randomization study.
  • Antibacterial toner exhibits bactericidal effect against Cutibacterium acnes via keratin and sebum plug penetration.

Clinical Reviews

  • Efficacy of topical treatments for mild-to-moderate acne: A systematic review and meta-analysis of randomized control trials.
  • Targeting sebaceous glands: A review of selective photothermolysis for acne vulgaris treatment.
  • Metformin therapy for acne vulgaris: A meta-analysis.
  • Topical clindamycin in the management of acne vulgaris: Current perspectives and recent therapeutic advances.
  • Common skin conditions in children and adolescents: Acne.
  • Updates on topical dyad and triple combination therapies approved for acne vulgaris.
  • The effect of isotretinoin on insulin resistance and serum adiponectin levels in acne vulgaris patients: A systematic review and meta-analysis.

Related Posts

Volume: June 2024, Issue 1

Volume: June 2024, Issue 1

AARS News   Highlights from the 11th Annual AARS Annual Scientific Symposium New Medical Research Isotretinoin for acne in transgender and gender-diverse individuals receiving masculinizing hormone therapy. Efficacy and safety of bimekizumab in patients with...

Volume: May 2024, Issue 1

Volume: May 2024, Issue 1

AARS News   AARS Call for Grant Applications New Medical Research Triple combination clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% for acne: Efficacy and safety from a pooled phase 3 analysis. The role of vitamins and nutrients in rosacea....

Volume: April 2024, Issue 1

Volume: April 2024, Issue 1

AARS News   Register now for the 11th Annual AARS Scientific Symposium AARS Call for Grant Applications Response Statement from the American Acne & Rosacea Society to the Valisure Citizen Petition on Benzene in Benzoyl Peroxide Drug Products New Medical...

Volume: March 2024, Issue 1

Volume: March 2024, Issue 1

AARS News Register now for the 11th Annual AARS Scientific Symposium AARS Call for Grant Applications Response Statement from the American Acne & Rosacea Society to the Valisure Citizen Petition on Benzene in Benzoyl Peroxide Drug Products New Medical Research...